- ISIN
- US23284F1057
- CUSIP
- 23284F105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 8, 2015
Highlights
- Market Cap
- $538.91M
- Enterprise Value
- $515.79M
- EPS (TTM)
- -$0.37
- Total Revenue (TTM)
- $35.54M
- Gross Profit (TTM)
- $24.77M
- EBITDA (TTM)
- -$62.07M
- Year Range
- $1.72 - $8.21
- Target Price
- $11.60
- ROA (TTM)
- -16.46%
- ROE (TTM)
- -18.48%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CTMX Performance Chart
CytomX Therapeutics, Inc. (CTMX) is down 28.6% since the beginning of the year. At $3 per share, CTMX is trading 63.0% below its 52-week high of $8. Investors who bought $1,000 worth of CTMX shares 5 years ago would now be looking at an investment worth $455.
Loading charts...
Returns By Period
CytomX Therapeutics, Inc. (CTMX) has returned -28.64% so far this year and 31.03% over the past 12 months. Over the last ten years, CTMX has returned -11.07% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
CytomX Therapeutics, Inc.
- 1D
- 3.05%
- 1M
- -19.15%
- YTD
- -28.64%
- 6M
- -26.21%
- 1Y
- 31.03%
- 3Y*
- 25.44%
- 5Y*
- -14.57%
- 10Y*
- -11.07%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CTMX Monthly Returns History
Based on dividend-adjusted daily data since Oct 8, 2015, CTMX's average daily return is +0.12%, while the average monthly return is +1.55%. At this rate, an investment would double in approximately 3.8 years.
Historically, 42% of months were positive and 58% were negative. The best month was May 2025 with a return of +256.0%, while the worst month was Apr 2022 at -36.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, CTMX closed higher 48% of trading days. The best single day was May 1, 2024 with a return of +214.7%, while the worst single day was May 9, 2024 at -51.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 33.57% | -5.62% | -12.48% | -10.21% | -14.69% | -15.56% | -28.64% | ||||||
| 2025 | -17.48% | -20.33% | -6.11% | 17.07% | 256.04% | -14.34% | -3.52% | -6.85% | 56.37% | 11.91% | 19.89% | -0.47% | 313.59% |
| 2024 | -1.29% | 60.13% | -11.02% | -25.23% | 4.29% | -28.24% | 13.11% | -14.49% | -0.00% | -15.62% | 6.46% | -2.83% | -33.55% |
| 2023 | 68.75% | -20.37% | -29.77% | 7.95% | 4.91% | 0.58% | 1.16% | -13.79% | -14.00% | -14.73% | 26.36% | 11.51% | -3.13% |
| 2022 | 6.24% | -16.74% | -30.29% | -35.96% | -5.85% | 13.66% | -21.86% | 4.90% | -3.33% | -9.66% | 32.82% | -8.05% | -63.05% |
| 2021 | 5.50% | 13.60% | -1.53% | 21.09% | -23.50% | -11.59% | -14.53% | -5.36% | -0.59% | 16.50% | 11.47% | -34.49% | -33.89% |
Benchmark Metrics
CytomX Therapeutics, Inc. has an annualized alpha of 10.55%, beta of 1.41, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 08, 2015.
- This stock participated in 136.29% of S&P 500 Index downside but only 22.30% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.55%
- Beta
- 1.41
- R²
- 0.05
- Upside Capture
- 22.30%
- Downside Capture
- 136.29%
Return for Risk
Risk / Return Rank
CTMX ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for CytomX Therapeutics, Inc. (CTMX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CTMX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.70 | ||
| Sortino ratioReturn per unit of downside risk | -1.50 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.37 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | 0.55 | 2.78 | -2.24 |
| Martin ratioReturn relative to average drawdown | 1.29 | 12.44 | -11.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CytomX Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CytomX Therapeutics, Inc. was 98.74%, occurring on Apr 7, 2025. The portfolio has not yet recovered.
The current CytomX Therapeutics, Inc. drawdown is 91.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.74%Apr 2025 | 7y 27d | — | 8y 3moMar 2018 - now |
2016 bear market2016 | -60.90%Jun 2016 | 6mo 13d | 1y 6mo | 2y 1moDec 2015 - Jan 2018 |
2015 bear market2015 | -41.88%Oct 2015 | 14d | 1mo 3d | 1mo 17dOct 2015 - Nov 2015 |
2018 pullback2018 | -4.10%Mar 2018 | 0s | 1d | 1dMar 2018 - Mar 2018 |
2018 pullback2018 | -3.64%Feb 2018 | 0s | 6d | 6dFeb 2018 - Feb 2018 |
Drawdown Indicators
| CTMX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.74% | -56.78% | -41.96% |
Max Drawdown (1Y)Largest decline over 1 year | -56.89% | -9.10% | -47.79% |
Max Drawdown (3Y)Largest decline over 3 years | -91.59% | -18.90% | -72.69% |
Max Drawdown (5Y)Largest decline over 5 years | -94.16% | -25.43% | -68.73% |
Max Drawdown (10Y)Largest decline over 10 years | -98.74% | -33.92% | -64.82% |
Current DrawdownCurrent decline from peak | -91.12% | -1.80% | -89.32% |
Average DrawdownAverage peak-to-trough decline | -70.93% | -10.71% | -60.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.04% | 2.03% | +22.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CytomX Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CytomX Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CTMX relative to other companies in the Biotechnology industry. Currently, CTMX has a P/S ratio of 13.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CTMX in comparison with other companies in the Biotechnology industry. Currently, CTMX has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CTMX
Add CytomX Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CTMX